Form 4: Centene Director Christopher J. Coughlin Reports Acquisition of Common Stock
SEC Form 4 Filing
Director Christopher J. Coughlin reports acquiring 402 shares of Centene Corp common stock on September 30, 2024.
Summary
- Christopher J. Coughlin, a director of Centene Corp, filed a Form 4 with the SEC.
- The report indicates that Mr. Coughlin acquired 402 shares of Centene's common stock on September 30, 2024, at a price of $0 per share.
- Following the transaction, Mr. Coughlin beneficially owns 26,357.926 shares of Centene's common stock, which includes 2,916 shares of restricted stock units subject to vesting requirements.
- Mr. Coughlin also holds options to buy 10,000 shares of common stock at an exercise price of $80.57, exercisable from February 7, 2025, and expiring on February 7, 2032.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring shares can be seen as a vote of confidence, but the $0 acquisition price suggests it was likely a grant or award, diminishing the strength of the signal.
Positives
- The acquisition of shares by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.
Comparison to Industry Standards
- Comparing insider transactions to those of peers like UnitedHealth Group (UNH) or CVS Health (CVS) can provide context.
- Analyzing the frequency and size of insider buys and sells across the healthcare sector can help determine if this transaction is typical or noteworthy.
- Benchmarking the option exercise price against the current and historical stock prices of Centene and its competitors offers insights into the potential value of the options.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of common stock acquisition. |
| 02/07/2025 | Date common stock options become exercisable. |
| 02/07/2032 | Expiration date of common stock options. |
| 10/02/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.